The N-terminal domain (NTD) of the SARS-CoV-2 spike protein is an important target of neutralizing antibodies, yet its epitope map, modes of neutralization, and routes of immune escape have remained incompletely defined. The study summarized here set out to generate a structural and mechanistic atlas of NTD-directed antibody recognition and viral evasion across the prototype virus and multiple (sub-)variants, with the goal of clarifying antigenic organization and variant escape strategies.
Using structural and mapping approaches, the authors organized NTD-directed antibodies into nine spatially distinct classes, designated NTD-1 through NTD-9. This classification provides an epitope-resolved framework to compare antibodies that target different regions of the NTD and to interpret how specific mutations or structural changes in the domain affect recognition.
Within the classification, the authors identified a previously cryptic epitope defined as NTD-8. The designation points to antigenic surfaces that were not apparent in prior maps and underscores the structural complexity of the NTD antigenic landscape.
Mechanistic experiments indicated that antibodies from at least two classes, NTD-5 and NTD-9, neutralize virus in part by inducing S1 shedding of the spike protein. This observation extends S1 shedding as a neutralization mechanism to selected NTD-directed antibodies, demonstrating that engagement of certain NTD epitopes can destabilize the spike and promote subunit dissociation as an antiviral effect.
The study assessed antibody format dependence and found that, for most NTD antibodies, bivalency (intact IgG) is required to achieve neutralization. However, selected antibodies from NTD-3, NTD-5, and NTD-9 retained neutralizing activity in Fab (monovalent) form. This indicates that some NTD epitopes can be targeted effectively by a single antigen-binding fragment, while others depend on avidity or crosslinking afforded by full-length IgG.
The authors profiled a panel of 41 NTD antibodies against the SARS-CoV-2 prototype strain, Delta, and 17 Omicron subvariants. This epitope-resolved experimental set produced an escape landscape that links individual antibody classes and epitopes to patterns of sensitivity or resistance across variant spikes. The mapping enables direct comparison of how mutations present in different variants impact recognition by distinct NTD antibody classes.
Analysis of variant resistance patterns revealed three convergent immune evasion strategies used by SARS-CoV-2 (sub-)variants to escape NTD-directed antibodies:
Contact residue disruption: substitutions or deletions at residues directly contacted by antibodies that reduce or abolish binding.
Glycan shielding: introduction or repositioning of N-linked glycans that sterically block antibody access to epitopes.
Conformational remodeling: mutations and deletions that alter local structure or dynamics of the NTD, preventing antibody recognition even when direct contact residues are conserved.
These strategies can act independently or in combination depending on the variant and the targeted epitope.
A highlighted example in the atlas is the KP.3.1.1 subvariant, which employs a dual escape mechanism: a deletion (∆S31) that results in the introduction of an N30 glycosylation site, combined with substantial remodeling of the S27–R34 region. Together, these changes undermine recognition by antibodies from both the NTD-5 and NTD-9 classes, illustrating how combined glycan gain and structural remodeling can produce broad loss of neutralization by multiple antibody classes.
The atlas provides a structured map linking NTD epitope classes to neutralization mechanisms and variant escape tactics. Such a resource can inform interpretation of antibody potency against emerging variants, guide selection or engineering of therapeutic antibodies that target less mutable NTD sites or that retain activity in Fab form, and support genomic surveillance by highlighting mutations likely to impact NTD-directed immunity.
The source material summarized here is the article abstract. Specific experimental details such as structural resolution metrics, the full list and sequences of the 41 antibodies, quantitative neutralization titers, cryo-EM or crystallography datasets, and detailed methods were not reported in the abstract. For those technical data and full datasets, consult the full published article and supplementary materials.